Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005.
暂无分享,去创建一个
R. Gelber | A. Goldhirsch | A. Coates | J. Glick | B. Thürlimann | H. Senn | B Thürlimann | R D Gelber | A Goldhirsch | J H Glick | A S Coates | H-J Senn | Panel Members
[1] N. Davidson,et al. Adjuvant endocrine therapy for premenopausal women with early breast cancer , 2007, Breast Cancer Research.
[2] J. Overgaard,et al. Is the benefit of postmastectomy irradiation limited to patients with four or more positive nodes, as recommended in international consensus reports? A subgroup analysis of the DBCG 82 b&c randomized trials. , 2007, Radiotherapy and Oncology.
[3] H. Cody,et al. Redefining prognosis in node-negative breast cancer: Can sentinel lymph node biopsy raise the threshold for systemic adjuvant therapy? , 2004, Annals of Surgical Oncology.
[4] D. Berry. Chemotherapy is More Effective in Patients With Breast Cancer Not Expressing Steroid Hormone Receptors: A Study of Preoperative Treatment , 2006 .
[5] M. F. J. Michael Dixon MB ChB. Role of endocrine therapy in the neoadjuvant surgical setting , 2006, Annals of Surgical Oncology.
[6] M. Vijver,et al. Biological variables and prognosis of DCIS. , 2005 .
[7] Lesley Fallowfield,et al. Acceptance of adjuvant therapy and quality of life issues. , 2005, Breast.
[8] Daniel F Hayes,et al. Prognostic and predictive factors revisited. , 2005, Breast.
[9] M. Castiglione‐Gertsch,et al. Adjuvant endocrine therapies for postmenopausal women with early breast cancer: standards and not. , 2005, Breast.
[10] S. Aebi. Special issues related to the adjuvant therapy in very young women. , 2005, Breast.
[11] G. Viale. Histopathology of primary breast cancer 2005. , 2005, Breast.
[12] G. von Minckwitz,et al. Preoperative (neoadjuvant) systemic treatment of breast cancer. , 2005, Breast.
[13] R. Schiff,et al. Endocrine responsiveness: understanding how progesterone receptor can be used to select endocrine therapy. , 2005, Breast.
[14] M. Morrow. Limiting breast surgery to the proper minimum. , 2005, Breast.
[15] K. Pritchard,et al. Adjuvant endocrine therapies for pre-/perimenopausal women. , 2005, Breast.
[16] R. Gelber,et al. Predicting response to systemic treatments: learning from the past to plan for the future. , 2005, Breast.
[17] K. McMasters,et al. Preferences for different methods of communicating information regarding adjuvant chemotherapy for breast cancer , 2005, Psycho-oncology.
[18] Marek Pawlicki,et al. Adjuvant docetaxel for node-positive breast cancer. , 2005, The New England journal of medicine.
[19] Terry L. Smith,et al. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] A. Goldhirsch,et al. Timing of CMF chemotherapy in combination with tamoxifen in postmenopausal women with breast cancer: role of endocrine responsiveness of the tumor. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.
[21] R. Arriagada,et al. Randomized trial of adjuvant ovarian suppression in 926 premenopausal patients with early breast cancer treated with adjuvant chemotherapy. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.
[22] A. Luini,et al. Size of breast cancer metastases in axillary lymph nodes: clinical relevance of minimal lymph node involvement. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] J. Ferlay,et al. Cancer incidence and mortality in Europe, 2004. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.
[24] K. Osborne. Speakers' AbstractS8 Endocrine Responsiveness: Understanding How Progesterone Receptor Can be Used to Select Endocrine Therapy , 2005 .
[25] G. Vial. Speakers' AbstractS12 Histopathology of Primary Breast Cancer 2005 , 2005 .
[26] J. Petit. S20 Nipple Sparing Mastectomy in Association with IntraOperative Radiotherapy: A New Type of Mastectomy for Breast Cancer Treatment , 2005 .
[27] M. Dowsett. S9 The Biology of Steroid Hormones and Endocrine Therapies , 2005 .
[28] A. Borq. S10 The Biology of BRCA 1/2 and Beyond , 2005 .
[29] J. Garber. S2 Genetic counseling: Therapeutic consequences , 2005 .
[30] M. Intra,et al. S17 Sentinel Lymphnodes for Localized DCIS , 2005 .
[31] S. Aebi. S32 Special Issues Related to Adjuvant Therapy in Very Young Women , 2005 .
[32] M. Castiglione‐Gertsch. S24 Adjuvant Endocrine Therapies for PostmenopausalWomen: Standards and Not , 2005 .
[33] J. Bellon,et al. S22 Which extent of Adjuvant Radiotherapy is Standard , 2005 .
[34] R. Orecchia. S21 Intraoperative Radiation Therapy to the Breast , 2005 .
[35] L. Fallowfiel. S34 Acceptance of Adjuvant Endocrine Therapies and Quality of Life Issues , 2005 .
[36] K. Albain. S25 Do All Patients with Endocrine-Responsive EarlyBreast Cancer Need Adjuvant Chemotherapy before Endocrine Treatment? , 2005 .
[37] R. Greil,et al. P81 Benefits of switching postmenopausal women withhormone-sensitive early breast cancer to anastrozole after 2 years adjuvant tamoxifen: combined results from 3123 women enrolled in the ABCSG Trial 8 and the ARNO 95 Trial , 2005 .
[38] N. Harbeck. P40 Pooled analysis (n=8,377) validates predictive impactof uPA and PAI-1 for response to adjuvant chemotherapy in breast cancer , 2005 .
[39] P Kelly Marcom,et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[40] John J Spinelli,et al. Locoregional radiation therapy in patients with high-risk breast cancer receiving adjuvant chemotherapy: 20-year results of the British Columbia randomized trial. , 2005, Journal of the National Cancer Institute.
[41] G. Bonadonna,et al. 30 years' follow up of randomised studies of adjuvant CMF in operable breast cancer: cohort study , 2005, BMJ : British Medical Journal.
[42] K. Offit,et al. Hereditary cancer predisposition syndromes. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[43] W. Gerald,et al. Distinct organ-specific metastatic potential of individual breast cancer cells and primary tumors. , 2005, The Journal of clinical investigation.
[44] M Baum,et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer , 2005, The Lancet.
[45] James N Ingle,et al. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[46] I. Bedrosian. The prognostic implication of the basal-like (cyclin Ehigh/ p27low/p53+glomeruloid-microvascular-proliferation +) phenotype of BRCA1-related breast cancer , 2005 .
[47] M. J. van de Vijver. Biological variables and prognosis of DCIS. , 2005, Breast.
[48] L. Solin,et al. Impact of concurrent versus sequential tamoxifen with radiation therapy in early-stage breast cancer patients undergoing breast conservation treatment. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[49] B. Haffty,et al. Sequence of radiotherapy with tamoxifen in conservatively managed breast cancer does not affect local relapse rates. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[50] Peter Boyle,et al. Cancer incidence and mortality in Europe , 2005, Sozial- und Präventivmedizin.
[51] M. Cronin,et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. , 2004, The New England journal of medicine.
[52] N. Wolmark,et al. Treatment of axillary lymph node-negative, estrogen receptor-negative breast cancer: updated findings from National Surgical Adjuvant Breast and Bowel Project clinical trials. , 2004, Journal of the National Cancer Institute.
[53] L. Schover. Myth-busters: telling the true story of breast cancer survivorship. , 2004, Journal of the National Cancer Institute.
[54] J. Foekens,et al. Urokinase-type plasminogen activator and its inhibitor type 1 predict disease outcome and therapy response in primary breast cancer. , 2004, Clinical breast cancer.
[55] S. Schraub,et al. Disease-free survival advantage of weekly epirubicin plus tamoxifen versus tamoxifen alone as adjuvant treatment of operable, node-positive, elderly breast cancer patients: 6-year follow-up results of the French adjuvant study group 08 trial. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[56] C. Gateley,et al. Tamoxifen and pregnancy. , 2004, Breast.
[57] S. Cummings,et al. Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene. , 2004, Journal of the National Cancer Institute.
[58] A. Goldhirsch,et al. Minimal and small size invasive breast cancer with no axillary lymph node involvement: the need for tailored adjuvant therapies. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.
[59] R. Jagsi,et al. The management of ductal carcinoma in situ in North America and Europe , 2004, Cancer.
[60] L. Fallowfield,et al. Same gain, less pain: potential patient preferences for adjuvant treatment in premenopausal women with early breast cancer. , 2004, European journal of cancer.
[61] E. Perez,et al. Future options with trastuzumab for primary systemic and adjuvant therapy. , 2004, Seminars in oncology.
[62] A. Sapino,et al. Meta‐analysis of non‐sentinel node metastases associated with micrometastatic sentinel nodes in breast cancer , 2004, The British journal of surgery.
[63] C. Davies. Switching to exemestane after 2-3 years of adjuvant tamoxifen prolongs disease-free survival, but not overall survival, in postmenopausal women surviving primary breast cancer, compared with continuous tamoxifen. , 2004, Cancer treatment reviews.
[64] P. Ravdin,et al. A method for making estimates of the benefit of the late use of letrozole in patients completing 5 years of tamoxifen. , 2004, Clinical breast cancer.
[65] M. Clarke,et al. Self-renewal and solid tumor stem cells , 2004, Oncogene.
[66] B. Hillner. Benefit and projected cost‐effectiveness of anastrozole versus tamoxifen as initial adjuvant therapy for patients with early‐stage estrogen receptor–positive breast cancer , 2004, Cancer.
[67] Melania Pintilie,et al. Tamoxifen with or without breast irradiation in women 50 years of age or older with early breast cancer. , 2004, The New England journal of medicine.
[68] Barbara L. Smith,et al. Lumpectomy plus tamoxifen with or without irradiation in women 70 years of age or older with early breast cancer. , 2004, The New England journal of medicine.
[69] S. Ménard,et al. Pilot Study of the Mechanism of Action of Preoperative Trastuzumab in Patients with Primary Operable Breast Tumors Overexpressing HER2 , 2004, Clinical Cancer Research.
[70] N. Davidson,et al. What is the role of ovarian ablation in the management of primary and metastatic breast cancer today? , 2004, The oncologist.
[71] J. Nesland,et al. Isolated Tumor Cells in Bone Marrow Three Years after Diagnosis in Disease-Free Breast Cancer Patients Predict Unfavorable Clinical Outcome1 , 2004, Clinical Cancer Research.
[72] M. Untch,et al. Her-2/neu gene amplification and response to paclitaxel in patients with metastatic breast cancer. , 2004, Journal of the National Cancer Institute.
[73] M. Piccart,et al. Adjuvant therapy in elderly patients with breast cancer. , 2004, Clinical breast cancer.
[74] J. Bonneterre,et al. Long-term cardiac follow-up in relapse-free patients after six courses of fluorouracil, epirubicin, and cyclophosphamide, with either 50 or 100 mg of epirubicin, as adjuvant therapy for node-positive breast cancer: French adjuvant study group. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[75] Michael Gnant,et al. Prognostic Value of Lymphangiogenesis and Lymphovascular Invasion in Invasive Breast Cancer , 2004, Annals of surgery.
[76] H. D. de Koning,et al. Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition. , 2004, The New England journal of medicine.
[77] A. Goldhirsch,et al. Metronomic oral chemotherapy (CT) versus the same regimen in association with Thalidomide (TLM): results of a randomized trial in patients (pts) with advanced breast cancer (ABC) , 2004 .
[78] K. Gelmon,et al. An independent population-based validation of the adjuvant decision-aid for stage I-II breast cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[79] L. Schwartzberg,et al. Randomized phase IIb trial comparing two schedules of docetaxel (D) plus estramustine (E) for metastatic hormone refractory prostate cancer (HRPC). , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[80] V. Semiglazov,et al. The relative efficacy of neoadjuvant endocrine therapy vs chemotherapy in postmenopausal women with ER- positive breast cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[81] Stine Korreman,et al. Breathing adapted radiotherapy of breast cancer: reduction of cardiac and pulmonary doses using voluntary inspiration breath-hold. , 2004, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[82] S. Ropero,et al. Trastuzumab Plus Tamoxifen: Anti-Proliferative and Molecular Interactions in Breast Carcinoma , 2004, Breast Cancer Research and Treatment.
[83] N. Brünner,et al. Urokinase-Type Plasminogen Activator System in Breast Cancer , 2004, Cancer Research.
[84] A. Bofin,et al. Detection and quantitation of HER-2 gene amplification and protein expression in breast carcinoma. , 2004, American journal of clinical pathology.
[85] R. Schiff,et al. Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. , 2004, Journal of the National Cancer Institute.
[86] G. Hortobagyi,et al. Breast conservation after neoadjuvant chemotherapy: the MD Anderson cancer center experience. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[87] P. Philip,et al. Factors associated with breast cancer clinical trials participation and enrollment at a large academic medical center. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[88] J. Palazzo,et al. The prognostic significance of multiple morphologic features and biologic markers in ductal carcinoma in situ of the breast , 2004, Cancer.
[89] Robert S. Kerbel,et al. The anti-angiogenic basis of metronomic chemotherapy , 2004, Nature Reviews Cancer.
[90] J. Nesland,et al. The Prognostic Value of Isolated Tumor Cells in Bone Marrow in Breast Cancer Patients , 2004, Clinical Cancer Research.
[91] M. Gnant,et al. High nuclear grade and negative estrogen receptor are significant risk factors for recurrence in DCIS. , 2004, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.
[92] E. Rutgers. Follow-up care in breast cancer , 2004, Expert review of anticancer therapy.
[93] J. Bellon,et al. A prospective study of concurrent cyclophosphamide/methotrexate/5‐fluorouracil and reduced‐dose radiotherapy in patients with early‐stage breast carcinoma , 2004, Cancer.
[94] Susan L Neuhausen,et al. Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[95] P. Lønning,et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer* , 2004, The New England journal of medicine.
[96] A. Ochiai,et al. Histological characteristics of tumor in vessels and lymph nodes are significant predictors of progression of invasive ductal carcinoma of the breast: a prospective study. , 2004, Human pathology.
[97] D. Brewster,et al. Improvements in survival for women with breast cancer in Scotland between 1987 and 1993: impact of earlier diagnosis and changes in treatment. , 2004, European journal of cancer.
[98] H. Bartelink,et al. Workshop on partial breast irradiation: state of the art and the science, Bethesda, MD, December 8-10, 2002. , 2004, Journal of the National Cancer Institute.
[99] L. Bégin,et al. The Prognostic Implication of the Basal-Like (Cyclin Ehigh/p27low/p53+/Glomeruloid-Microvascular-Proliferation+) Phenotype of BRCA1-Related Breast Cancer , 2004, Cancer Research.
[100] K. Strasser-Weippl,et al. Prevention Strategies with Aromatase Inhibitors , 2004, Clinical Cancer Research.
[101] S. Conzen,et al. Invariant p53 immunostaining in primary and recurrent breast cancer. , 2004, European journal of cancer.
[102] A. Goldhirsch,et al. Metronomic oral chemotherapy (CT) versus the same regimen in association with Thalidomide (TLM): results of a randomized trial in patients (pts) with advanced breast cancer (ABC). , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[103] A. Coates,et al. Randomized comparison of adjuvant tamoxifen (Tam) versus no hormonal treatment for premenopausal women with node-positive (N+), early stage breast cancer: first results of International Breast Cancer Study Group Trial 13-93. , 2004, Journal of Clinical Oncology.
[104] K. Knutson,et al. Peptide-based Vaccines in Breast Cancer , 2022 .
[105] M. Bonetti,et al. Adjuvant chemotherapy followed by goserelin versus either modality alone for premenopausal lymph node-negative breast cancer: a randomized trial. , 2003, Journal of the National Cancer Institute.
[106] R. Gelber,et al. Adjuvant endocrine therapy compared with no systemic therapy for elderly women with early breast cancer: 21-year results of International Breast Cancer Study Group Trial IV. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[107] E. Perez,et al. A Randomized Trial of Letrozole in Postmenopausal Women after Five Years of Tamoxifen Therapy for Early-Stage Breast Cancer , 2003 .
[108] C. Isaacs,et al. Bilateral prophylactic oophorectomy and ovarian cancer screening following BRCA1/BRCA2 mutation testing. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[109] A. E. Hirsch,et al. Novel approaches to postoperative radiation therapy as part of breast-conserving therapy for early-stage breast cancer. , 2003, Clinical breast cancer.
[110] R. Gelber,et al. Meeting highlights: updated international expert consensus on the primary therapy of early breast cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[111] Philip M. Long,et al. Breast cancer classification and prognosis based on gene expression profiles from a population-based study , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[112] K. Bloom,et al. The Her-2/neu gene and protein in breast cancer 2003: biomarker and target of therapy. , 2003, The oncologist.
[113] R. Tibshirani,et al. Repeated observation of breast tumor subtypes in independent gene expression data sets , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[114] T. Nishikawa,et al. The combination of angiogenesis and blood vessel invasion as a prognostic indicator in primary breast cancer , 2003, British Journal of Cancer.
[115] W. Carney,et al. Serum HER-2/neu and response to the aromatase inhibitor letrozole versus tamoxifen. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[116] R. Carlson,et al. Treatment of Breast Cancer in Countries with Limited Resources , 2003, The breast journal.
[117] Barbara L. Smith,et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[118] C. Boland,et al. BRCA1 expression modulates chemosensitivity of BRCA1-defective HCC1937 human breast cancer cells , 2003, British Journal of Cancer.
[119] S. Morrison,et al. Prospective identification of tumorigenic breast cancer cells , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[120] M. Piccart,et al. Final results of a randomized phase III trial comparing cyclophosphamide, epirubicin, and fluorouracil with a dose-intensified epirubicin and cyclophosphamide + filgrastim as neoadjuvant treatment in locally advanced breast cancer: an EORTC-NCIC-SAKK multicenter study. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[121] D. DeMets,et al. Her-2/neu overexpression and response to oophorectomy plus tamoxifen adjuvant therapy in estrogen receptor-positive premenopausal women with operable breast cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[122] Michael B Sharpe,et al. Significant reductions in heart and lung doses using deep inspiration breath hold with active breathing control and intensity-modulated radiation therapy for patients treated with locoregional breast irradiation. , 2003, International journal of radiation oncology, biology, physics.
[123] Lisa Barbera,et al. Does delay in starting treatment affect the outcomes of radiotherapy? A systematic review. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[124] Barbara L. Smith,et al. Preoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin/cyclophosphamide for HER2 overexpressing stage II or III breast cancer: a pilot study. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[125] D. Cameron,et al. Block sequential adriamycin CMF – optimal non-myeloablative chemotherapy for high risk adjuvant breast cancer? , 2002, British Journal of Cancer.
[126] R. Gelber,et al. Overhauling the breast cancer overview: are subsets subversive? , 2002, The Lancet. Oncology.
[127] Can We Select Which Patients With Small Breast Cancers Should Receive Adjuvant Chemotherapy? , 2002, Annals of surgery.
[128] Susan L Neuhausen,et al. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. , 2002, The New England journal of medicine.
[129] Anthony J. Guidi,et al. Association of angiogenesis and disease outcome in node-positive breast cancer patients treated with adjuvant cyclophosphamide, doxorubicin, and fluorouracil: a Cancer and Leukemia Group B correlative science study from protocols 8541/8869. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[130] Van,et al. A gene-expression signature as a predictor of survival in breast cancer. , 2002, The New England journal of medicine.
[131] R. Gray,et al. Adjuvant therapy for very young women with breast cancer: need for tailored treatments. , 2001, Journal of the National Cancer Institute. Monographs.
[132] M. Mesiti,et al. Sequential tamoxifen and aminoglutethimide versus tamoxifen alone in the adjuvant treatment of postmenopausal breast cancer patients: results of an Italian cooperative study. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[133] L. Holmberg,et al. Increased p53 mutation frequency during tumor progression--results from a breast cancer cohort. , 2001, Cancer research.
[134] I. Barillot,et al. Recurrence rates after treatment of breast cancer with standard radiotherapy with or without additional radiation. , 2001, The New England journal of medicine.
[135] M. Stockler,et al. Patients' preferences for adjuvant chemotherapy in early breast cancer: a review of what makes it worthwhile. , 2001, The Lancet. Oncology.
[136] R. Gelber,et al. Influence of endocrine-related factors on response to perioperative chemotherapy for patients with node-negative breast cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[137] D B Evans,et al. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[138] E. Dees,et al. Ovarian ablation as adjuvant therapy for breast cancer. , 2001, Seminars in oncology.
[139] R. Blamey,et al. Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: a meta-analysis of four randomized trials. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[140] J. Bergh,et al. Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: a randomised trial , 2000, The Lancet.
[141] M. Bonetti,et al. Early start of adjuvant chemotherapy may improve treatment outcome for premenopausal breast cancer patients with tumors not expressing estrogen receptors. The International Breast Cancer Study Group. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[142] L. Solin,et al. Treatment of early-stage breast cancer in elderly women. , 2000, Medical and pediatric oncology.
[143] I. Ellis,et al. Pathological prognostic factors in breast cancer. , 1999, Critical reviews in oncology/hematology.
[144] D. Joseph,et al. Simultaneous adjuvant radiotherapy and chemotherapy for stage I and II breast cancer. , 1999, Australasian radiology.
[145] C K Osborne,et al. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[146] Mike Clarke,et al. Polychemotherapy for early breast cancer: an overview of the randomised trials , 1998, The Lancet.
[147] Mike Clarke,et al. Tamoxifen for early breast cancer: an overview of the randomised trials , 1998, The Lancet.
[148] D. Allred,et al. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. , 1998, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.
[149] J. Coindre,et al. Obvious peritumoral emboli: an elusive prognostic factor reappraised. Multivariate analysis of 1320 node-negative breast cancers. , 1998, European journal of cancer.
[150] R. Collins,et al. Ovarian ablation in early breast cancer: overview of the randomised trials , 1996, The Lancet.
[151] J. Forbes,et al. Impact of adjuvant therapy on quality of life in women with node-positive operable breast cancer , 1996, The Lancet.
[152] M. Piccart,et al. Adjuvant systemic therapy for breast cancer. , 1995, Current opinion in oncology.
[153] S. Pinder,et al. Pathological prognostic factors in breast cancer. III. Vascular invasion: relationship with recurrence and survival in a large study with long‐term follow‐up , 1994, Histopathology.
[154] J. Dragovic. Intraoperative radiation therapy. , 1992, Japanese journal of cancer research : Gann.
[155] T. Powles,et al. Treatment of breast cancer with aromatase inhibitors--current status and future prospects. , 1989, British Journal of Cancer.
[156] G. Falkson,et al. CAF and nasal buserelin in the treatment of premenopausal women with metastatic breast cancer. , 1989, European journal of cancer & clinical oncology.
[157] J. Bull,et al. A randomized comparative trial of adriamycin versus methotrexate in combination drug therapy , 1978, Cancer.
[158] F. Roe. Cancer Treatment , 1971, Nature.
[159] A POMBAL,et al. [Results of a survey]. , 1955, Jornal do medico.
[160] F W MULSOW,et al. Cancer incidence and mortality , 2019, Health at a Glance: Europe.